Nathan Denlinger

Statistics

Publications

Citations

467

H-Index

Active since

2007

Affiliations

The Ohio State University(Current)

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Dana-Farber Cancer Institute

Medical College of Wisconsin

Huntsman Cancer Institute

Nathan Denlinger is an author at The Ohio State University specializing in cancer immunotherapy, oncology, and chimeric antigen receptor t-cell therapy.

ORCID

Publications per year

2007–2024

Publications

Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML

H. Moses Murdock, Haesook T. Kim, Nathan Denlinger et al. · Blood · 2022 · 74 citations · Full text

Life Sciences, Genetics, Geriatric Medicine +13

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma

Joanna Zurko, Jeremy Ramdial, Mazyar Shadman et al. · Haematologica · 2022 · 74 citations · Full text

Life Sciences, Hematology, Immunology +15

Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma

Jonathan E. Brammer, Zachary Braunstein, Aashish Katapadi et al. · Journal for ImmunoTherapy of Cancer · 2021 · 61 citations · Full text

Medicine, Immunology, Oncology +17

Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis

Adam S. Kittai, Ying Huang, Max J. Gordon et al. · Transplantation and Cellular Therapy · 2020 · 60 citations

Medicine, Hematology, Oncology +17

Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL

Joanna Zurko, Imran Nizamuddin, Narendranath Epperla et al. · Blood Advances · 2022 · 50 citations · Full text

Life Sciences, Immunology, Oncology +14

1–5 of 12